J&J to acquire lower-priced Omrix
This article was originally published in Scrip
Executive Summary
Johnson & Johnsonis to acquire Omrix Biopharmaceuticals for around $438 million in a cash tender offer. Omrix, a developer of protein-based biosurgery and passive immunotherapy products, is expected to operate as a stand-alone entity reporting through J&J's surgical procedures subsidiary Ethicon, with which it has worked closely for the past five years.